Related references
Note: Only part of the references are listed.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Immunotherapy of renal cell carcinoma
Cecile Gouttefangeas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Molecular pathways in renal cell carcinoma- Rationate for targeted treatment
William Y. Kim et al.
SEMINARS IN ONCOLOGY (2006)
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer:: a review
P. Schoffski et al.
ANNALS OF ONCOLOGY (2006)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni et al.
BLOOD (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
Jan Wierecky et al.
CANCER RESEARCH (2006)
TLR signaling
T Kawai et al.
CELL DEATH AND DIFFERENTIATION (2006)
Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement
T Nakahara et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2006)
被撤回的出版物: The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells (Retracted article. See vol. 79, pg. 5459, 2019)
DJ Panka et al.
CANCER RESEARCH (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Regulatory T cells in ovarian cancer: Biology and therapeutic potential
B Barnett et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2005)
Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex
Y Kanno et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
M Moore et al.
ANNALS OF ONCOLOGY (2005)
Critical roles of Raf/MEKIERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells
J Xie et al.
EXPERIMENTAL HEMATOLOGY (2005)
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways
S Appel et al.
CLINICAL CANCER RESEARCH (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivoi
ML Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Innate recognition of lipopolysaccharide by toll-like receptor 4-MD-2
K Miyake
TRENDS IN MICROBIOLOGY (2004)
ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells
G Schiavoni et al.
BLOOD (2004)
Identification of a TLR4- and TRIF-dependent activation program of dendritic cells
H Weighardt et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Activation of dendritic cells: translating innate into adaptive immunity
CRE Sousa
CURRENT OPINION IN IMMUNOLOGY (2004)
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells
S Appel et al.
BLOOD (2004)
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
MJ Turk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Inferences, questions and possibilities in toll-like receptor signalling
B Beutler
NATURE (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dentritic cell activation and expansion of virus-specific CD8+ T cell memory responses
QG Yu et al.
JOURNAL OF IMMUNOLOGY (2004)
Essential role of IRF-3 in lipopolysaccharide-induced interferon-β gene expression and endotoxin shock
S Sakaguchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
NF-κB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase
MR Waterfield et al.
MOLECULAR CELL (2003)
Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-γ-independent mechanism:: Regulation by inflammatory and T cell-derived stimuli
A Nencioni et al.
EXPERIMENTAL HEMATOLOGY (2002)
Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells
A Puig-Kröger et al.
BLOOD (2001)
Discovery of a novel Raf kinase inhibitor
JF Lyons et al.
ENDOCRINE-RELATED CANCER (2001)
Differential expression of the transcription factor NF-κB during human mononuclear phagocyte differentiation to macrophages and dendritic cells
C Ammon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
